摘要
目的观察尤瑞克林联合奥扎格雷钠治疗急性脑梗死的临床效果。方法选取我院神经内科2012-01—2013-12收治的急性脑梗死患者163例,按随机数字表法分为对照组与观察组,对照组采取奥扎格雷钠80mg加入100mL 0.9%氯化钠注射液中静滴,2次/d,观察组在对照组治疗的基础上加用尤瑞克林0.15PNAU加入100mL 0.9%氯化钠注射液中静滴,1次/d,2组均治疗14d为1个疗程。治疗1个疗程后按美国国立卫生研究院卒中量表评分(NIHSS)评定2组患者神经功能恢复程度及临床疗效,记录2组治疗过程中的不良反应并对比分析。结果 2组治疗后NIHSS评分均较治疗前有所降低,观察组NIHSS评分显著低于对照组,差异有统计学意义(P<0.05);对照组总有效率79.0%,观察组为93.9%,2组比较差异有统计学意义(P<0.01);2组不良反应均较轻微,差异无统计学意义(P>0.05)。结论尤瑞克林联合奥扎格雷钠治疗急性脑梗死具有较好疗效,安全可靠,值得临床推广。
Objective To observe the clinical effect of urinary kallidinogenase combined with sodium ozagrel in the treat-ment of acute cerebral infarction. Methods 163 patients with acute cerebral infarction were selected in the department of Neu-rology in our hospital from January 2012 to December 2013 ,and randomly divided into control group and observation group ,81 cases in the control group were treated by sodium ozagrel 80mg added 100 mL 0.9% Sodium Chloride Injection intravenous drip ,2 times /d ,82 cases of the observation group were treated by urinary kallidinogenase 0.15 PNAU added 100mL 0.9% so-dium chloride Injection intravenous drip based on the control group treatment ,1 times /d. Both groups were treated for 14 days as one course. After 1 course of treatment ,USA National Institutes of Health Stroke Scale （NIHSS） was used to evaluate the degree of nerve function recovery and clinical efficacy of patients of the two groups ,adverse reactions of the two groups in the course of treatment were recorded and compared. Results After treatment ,NIHSS scores of the two groups were lower than those before treatment ;NIHSS score of patients in the observation group were significantly lower than that of the control group ,the difference was statistically significant （P0.05）.Conclusion The clinical effectiveness of urinary kallidinogenase com-bined with sodium ozagrel in the treatment of acute cerebral infarction is good ,safe and reliable ,and worthy of clinical applica-tion.
出处
《中国实用神经疾病杂志》
2014年第12期31-33,共3页
Chinese Journal of Practical Nervous Diseases
关键词
尤瑞克林
奥扎格雷钠
急性脑梗死
Urinary kallidinogenase
sodium ozagrel
acute cerebral infarction
